Global X S&P Biotech ETF (ASX:CURE)
Australia
· Delayed Price · Currency is AUD 63.53
+0.68 (1.08%)
Dec 5, 2025, 3:47 PM AEST
22.24% (1Y)
| Assets | 39.35M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +22.24% |
| Volume | 1,594 |
| Open | 62.84 |
| Previous Close | 62.85 |
| Day's Range | 62.84 - 63.53 |
| 52-Week Low | 38.76 |
| 52-Week High | 64.70 |
| Beta | 1.08 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 22.24% in the past year. Since the fund's inception, the average annual return has been 7.18%, including dividends.
Top 10 Holdings
22.49% of assets| Name | Symbol | Weight |
|---|---|---|
| Exact Sciences Corporation | EXAS | 2.87% |
| Revolution Medicines, Inc. | RVMD | 2.63% |
| Avidity Biosciences, Inc. | RNA | 2.39% |
| Insmed Incorporated | INSM | 2.25% |
| Natera, Inc. | NTRA | 2.14% |
| BridgeBio Pharma, Inc. | BBIO | 2.10% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.10% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 2.09% |
| Ionis Pharmaceuticals, Inc. | IONS | 1.99% |
| Biogen Inc. | BIIB | 1.94% |